A Study Comparing Valsartan With And Without Hydrochlorothiazide In Patients With Hypertension
Information source: Novartis
Information obtained from ClinicalTrials.gov on March 21, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Hypertension
Intervention: VALSARTAN, VALSARTAN+HYDROCHLOROTHIAZIDE (Drug)
Phase: Phase 3
Status: Completed
Sponsored by: Novartis Official(s) and/or principal investigator(s):
Novartis Pharmaceuticals, Study Chair, Affiliation: Novartis
Summary
SAFETY EXTENSION STUDY TO THE CORE STUDY CVAH631C2301
Clinical Details
Official title: A Study Comparing Valsartan With And Without Hydrochlorothiazide In Patients With Hypertension
Study design: Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study
Primary outcome: Adverse events and serious adverse events at each study visit for 54 weeks
Secondary outcome: Change from baseline in diastolic blood pressure from baseline after 54 weeksChange from baseline in systolic blood pressure from baseline after 54 weeks Change from baseline in standing diastolic and systolic blood pressure after 54 weeks Hematology and blood chemistries up to 54 weeks Physical condition including pregnancy, pulse and weight at each study visit
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
SUCCESSFUL COMPLETION OF STUDY CVAH631C2301
-
Exclusion Criteria:
- NONE
Locations and Contacts
Novartis Pharmaceuticals, East Hanover, New Jersey 07936, United States
Novartis Pharmaceuticals, East Hanover, New Jersey 07936, United States
Additional Information
Starting date: December 2003
Last updated: June 1, 2006
|
